A Urokinase Receptor-Bim Signaling Axis Emerges During EGFR Inhibitor Resistance in Mutant EGFR Glioblastoma

EGFR is the most common genetically altered oncogene in glioblastoma (GBM), but small molecule EGFR tyrosine kinase inhibitors (TKIs) have failed to yield durable clinical benefit. Here we show that in two novel model systems of acquired resistance to EGFR TKIs, elevated expression of urokinase plas...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:Cancer Res
Main Authors: Wykosky, Jill, Hu, Jingjing, Gomez, German G., Taylor, Tiffany, Villa, Genaro R., Pizzo, Donald, VandenBerg, Scott R., Thorne, Amy Haseley, Chen, Clark C., Mischel, Paul S., Gonias, Steven. L., Cavenee, Webster K., Furnari, Frank B.
Format: Artigo
Jezik:Inglês
Izdano: 2014
Teme:
Article
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC4297573/
https://ncbi.nlm.nih.gov/pubmed/25432173
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/0008-5472.CAN-14-2004
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki